深水海納(300961.SZ):擬出資4427.82萬元設立衡水深水海納水務有限公司
格隆匯12月20日丨深水海納(300961.SZ)公佈,公司近日中標雄安--故城產業生態城水生態系統建設特許經營項目,負責該項目指定區域內的淨水廠、中水廠經營活動(包含投融資、設計、建設、運營維護及期滿移交等所有內容),該項目總投資2.21億元,按照招標文件要求,項目公司由社會資本方出資組建,項目實施主體為公司擬設立的全資子公司衡水深水海納水務有限公司(暫定名,以下簡稱“項目公司”)。
項目公司擬由公司出資4427.82萬元人民幣設立,並由項目公司負責項目的投融資、建設及運營維護工作。
擬成立子公司經營範圍:供水、中水、排水(含污水處理)工程及運營管理、技術服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.